Belimumab Demonstrates Long-Term Safety, Efficacy in Systemic Lupus Erythematosus
Belimumab was well tolerated with no new safety concerns, and efficacy was maintained through 13 years of treatment.
Systemic Lupus Erythematosus
Predictors of Remission, Low Disease Activity State Identified in SLE
Researchers examined predictors of remission and low disease activity state in systemic lupus erythematosus.
Ethnicity May Not Contribute to Clinical Differences Between Adult-, Childhood-Onset SLE
Researchers sought to determine whether ethnic differences contribute to the differences in clinical presentation between patients with childhood-onset vs adult-onset SLE.
Comparing Sensitivities of Childhood-Onset SLE Classification: SLICC vs ACR Criteria
Researchers sought to compare the sensitivities of ACR and SLICC classification criteria in childhood-onset SLE.
Lupus Low Disease Activity State Discriminates Between Belimumab and Placebo in SLE Trials
Investigators examined the discriminant capacity of the Lupus Low Disease Activity State in a post-hoc analysis of belimumab data in systemic lupus erythematosus.
Assessing Pneumococcal Vaccine Immunogenicity in Systemic Lupus Erythematosus
Researchers conducted a post hoc analysis on antipneumococcal antibody responses in patients with SLE previously immunized with the 23-valent pneumococcal polysaccharide vaccine.
Elevated Fracture Risk Observed in SLE, Lupus Nephritis
Patients with systemic lupus erythematosus were at greater risk for fractures compared with controls.
Novel Index Developed to Measure Therapeutic Response in Childhood-Onset SLE
Researchers have developed highly accurate criteria to measure clinically relevant improvement of children and adolescents with systemic lupus erythematosus.
Predicting Treatment Success in Systemic Lupus Erythematosus-Associated PAH
Treatment success in systemic lupus erythematosus-associated pulmonary arterial hypertension, as defined by the European Society of Cardiology and the European Respiratory Society, is associated with long-term survival and supports a treat-to-target strategy.
Hepatitis A Vaccine Safe in Childhood-Onset SLE
Inactivated hepatitis A vaccine may be safe and well tolerated in childhood-onset systemic lupus erythematosus.
Next post in Systemic Lupus Erythematosus
